Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVD-133214 in Advanced Solid Tumors with MSI/dMMR
NCT06004245Phase 1Recruiting
- Sponsor
- Vividion Therapeutics
- Start
- Jan 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of VVD-133214 in solid tumor and colorectal cancer (CRC) (4 arms), sponsored by Vividion Therapeutics. Primary endpoints: Incidence of Adverse Events and Incidence of Dose-Limiting Toxicities. Started Jan 2024; status: recruiting.
02
Drugs
VVD-133214
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06004245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004245.